Sartorius Slashes 2023 View as Demand Shrinks Postpandemic
19 Junio 2023 - 12:42AM
Noticias Dow Jones
By Joshua Kirby
Sartorius expects declining sales and reduced profitability for
the year, it said late Friday, as a postpandemic slump continues to
drag the German pharmaceutical firm.
Sales should be lower in the low-to-mid teens of percent in 2023
than in the previous year, after climbing in 2022 to more than 4
billion euros ($4.38 billion). Sartorius had previously guided for
revenue growth in the low single digits this year.
Sartorius, which also makes laboratory equipment, said the worse
outlook is down to a lasting reduction in customers' inventories
after the Covid-19 boom, as well as reduced production
capacities.
As a result of the expected lower sales volumes, the group's
margin of underlying earnings before interest, taxes, depreciation
and amortization should contract to around 30% from 33.8% last
year, it said. The company had previously guided for a stable
margin on the year.
Sartorius made a weak start to 2023 when it reported its first
update in April, missing analysts' forecasts for first-quarter
sales and Ebitda as a result of destocking among customers.
The company meanwhile said it "views the current demand
normalization after the pandemic as a phase that only temporarily
overshadows the highly positive growth drivers of the life science
and biopharma markets," and backed its medium-term targets to
2025.
Write to Joshua Kirby at joshua.kirby@wsj.com;
@joshualeokirby
(END) Dow Jones Newswires
June 19, 2023 01:27 ET (05:27 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Sartorius (TG:SRT)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Sartorius (TG:SRT)
Gráfica de Acción Histórica
De May 2023 a May 2024